Go to London Stock Exchange Group Website

VEC  VECTURA GROUP PLC  ORD 0.025P

VECTURA  Currency GBX  Primary Listed Share

Company

Price +/- % +/- Bid Offer Volume High Low Last close
81.70 -2.30 -2.74% 81.70 82.70 500,369 83.45 82.10 81.70 on 20-Nov-2009
As at 21-Nov-2009 01:58:58 - All data delayed by at least 15 minutes.
This company is quoted on  Market

Share price performance

Last 5 trades
Time/Date Price Volume Trade value Type
16:35:29  20-Nov-09 81.70 22,375 18,280.38 UT
16:28:23  20-Nov-09 82.10 6,090 5,000.07 O
16:16:04  20-Nov-09 82.80 1,617 1,338.88 AT
16:16:04  20-Nov-09 82.70 100 82.70 AT
16:16:04  20-Nov-09 82.70 493 407.71 AT

Trading Information
21-Nov-2009
FTSE index FTSE All-Share,FTSE 350 Low Yield,FTSE 250,FTSE techMARK 100,FTSE MID 250 (ex IT),FTSE techMARK All-Share,FTSE techMARK mediscience,FTSE 350 (ex IT),FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment STMM
MiFID Status Regulated Market
Exchange market size 5,000
SEDOL B01D1K4
ISIN number GB00B01D1K48


Company Fundamentals
More
2009 (£m) 2008 (£m) 2007 (£m) 2006 (£m) 2005 (£m) 2005 (£m)
Currency GBP GBP GBP GBP GBP GBP
Total op. expenses -51.50 -49.99 -26.53 -16.89 -13.92 -14.05
P/L for the financial year -16.70 -19.21 -6.83 -6.46 -7.66 -7.79
Retained profit/loss -16.70 -19.21 -6.83 -6.46 -7.66 -7.79
Total assets 186.60 201.96 242.16 28.03 24.40 24.78
Total liabilities -186.60 -201.96 -242.16 -28.03 -24.40 -24.78

Latest news stories
More
Time/Date Headline
07:00 13-Nov-09    Notice of Results
07:00 02-Nov-09    Voting Rights and Capital
17:54 27-Oct-09    Holding(s) in Company
07:00 22-Oct-09    Update on NVA237 and QVA149 for COPD
17:16 07-Oct-09    Holding(s) in Company

Company Information
Updated Monthly
Company address Unit 1-3, Prospect West, Bumpers Way, Bumpers Farm, Chippenham, SN14 6FH, United Kingdom
Company website http://www.vectura.co.uk
Market cap(in millions)* £ 264.20
Listing/Admission to trading 18 Jul 2007
Trading system SETS
Market MAINMARKET
Activities A product development company focused on the development of a range of inhaled therapies; principally for the treatment of respiratory diseases
Auditor Deloitte Touche Tohmatsu
Financial Advisor Piper Jaffray Ltd
Broker Piper Jaffray Ltd
Solicitor Olswang
Registrar Computershare Ltd

*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are subject to change. Last updated: 20-Nov-2009



VECTURA price